Passer au contenu
OTR3, Science for Regeneration
  • Qui sommes-nous ?
  • Notre technologie
    • Technologie des RGTA®
    • Pipeline
    • Publications
  • Nos engagements
  • Notre activité commerciale
    • Dispositif médical pour l’homme
      • Cacipliq 20®
    • Produits vétérinaires
      • Clerapliq®
      • Dermapliq® Spray
    • Cosmétique Sportive
  • Actualités
  • Contact
  • Français
    • Français
    • English

Neuroprotection

  • April 2025 – Poster Session on the optimization of extracellular vesicles-based therapy in the treatment of ischemic stroke during the ISEV at Vienna

    Neuroprotection | News

    OPTIMIZATION OF EXTRACELLULAR VESICLES-BASED THERAPY IN THE TREATMENT OF ISCHEMIC STROKE Poster Session on the Friday 25th of April at 4:30PM at ISEV Congress in Vienna Ons BEN HADJ HASSEN1, Sarah RAZAFINDRAKOTO2, Jérôme TOUTAIN1, Isis BLANCHARD1, Viktoriia IVANOVA1, Charlène RENOULT1,3, Xavier LAFFRAY4, Minh-Bao HUYNH4, Carole BRUNAUD1, Karim BORDJI1, Gael LE [...]

  • March 2025 – OTR3 Announces First Patient Enrollment in Phase 2 Stroke Clinical Trial

    Neuroprotection | News

    OTR3 has initiated its Phase 2 clinical trial for OTR4132, a novel neuroprotector designed to enhance functional recovery in acute ischemic stroke patients following thrombectomy. A first-in-human pilot study, MATRISS, was conducted across three centers in France, evaluating six escalating doses. The results were promising, demonstrating favorable safety and efficacy [...]

OTR3, Science for Regeneration

Organes Tissus Régénération Réparation Remplacement

©2025 | OTR3 | All rights reserved.

  • Politique de confidentialité
  • Mentions légales
Kiwik, agence web à Orléans
Page load link
Aller en haut